摘要
目的探讨瑞舒伐他汀抗动脉粥样硬化的价值及其临床药理作用。方法选取我院(2017年1月至2019年1月)收治的114例颈动脉粥样硬化患者,均表现为不同程度的运动障碍、一过性肢体感觉等,根据不同药物治疗分为两组,对照组(n=57)接受阿司匹林治疗,观察组(n=57)接受瑞舒伐他汀治疗,对比两组患者治疗前后血脂指标(低密度脂蛋白胆固醇、三酰甘油、总胆固醇)和颈动脉内膜中层厚度以及不良反应(胃肠不适、荨麻疹、轻微血管神经性水肿)。结果治疗前观察组低密度脂蛋白胆固醇(3.70±1.12)mmol/L、三酰甘油(2.95±0.30)mmol/L、总胆固醇(5.90±1.71)mmol/L、颈动脉内膜中层厚度(0.98±0.10)mm,对照组分别为(3.71±1.11)mmol/L、(2.98±0.25)mmol/L、(5.87±1.75)mmol/L、(0.97±0.14)mm,治疗前两组患者血脂指标和颈动脉内膜中层厚度对比无差异(P>0.05);治疗后观察组低密度脂蛋白胆固醇(2.92±1.60)mmol/L,三酰甘油(1.86±0.16)mmol/L,总胆固醇(3.21±0.34)mmol/L,颈动脉内膜中层厚度(0.68±0.11)mm;对照组分别为(3.71±1.57)mmol/L,(2.10±0.48)mmol/L,(3.87±0.67)mmol/L,(0.78±0.17)mm。治疗后两组患者血脂指标和颈动脉内膜中层厚度均明显改善,观察组改善程度明显优于对照组(t=2.6607、3.5812、6.6321、3.7286,P<0.05)。观察组不良反应发生率5.26%(3/57),对照组8.77%(5/57),两组患者不良反应对比无差异(P>0.05)。结论瑞舒伐他汀具有良好的抗炎作用、可改善血管内皮功能、可抗氧化、抗血栓形成,瑞舒伐他汀在抗动脉粥样硬化的临床价值较高,值得推广应用。
Objective To study the anti atherosclerotic effect of rosuvastatin and its clinical pharmacology.Methods 114 patients with carotid atherosclerosis in our hospital from January 2017 to January 2019 were divided into two groups:control group(n=57)received aspirin treatment,observation group(n=57)received rosuvastatin treatment,and blood lipid index(low density)before and after treatment LDL-C,TG,TC)and carotid intima-media thickness as well as adverse reactions(gastrointestinal discomfort,urticaria,mild angioneuroedema).Results Observation group before treatment:low density lipoprotein cholesterol(3.70±1.12)mmol/L,triacylglycerol(2.95±0.30)mmol/L,total cholesterol(5.90±1.71)mmol/L,carotid intima media thickness(0.98±0.10)mm,the control group was(3.71±1.11)mmol/L,(2.98±0.25)mmol/L,(5.87±1.75)mmol/L,and(0.97±0.14)mm.There was no difference in carotid intima-media thickness(P>0.05);after treatment,the observation group had low-density lipoprotein cholesterol(2.92±1.60)mmol/L,triacylglycerol(1.86±0.16)mmol/L,and total cholesterol(3.21±0.34)mmol/L,carotid intima-media thickness(0.68±0.11)mm;control group was(3.71±1.57)mmol/L,(2.10±0.48)mmol/L,(3.87±0.67)mmol/L,(0.78±0.17)mm.After treatment,the blood lipid index and carotid intima-media thickness were significantly improved in the two groups,and the improvement in the observation group was signifi cantly better than that in the control group(t=2.6607,3.5812,6.6321,3.7286,P<0.05).The incidence of adverse reactions in the observation group was 5.26%(3/57)and in the control group was 8.77%(5/57).There was no difference in adverse reactions between the two groups(P>0.05).Conclusion Rosuvastatin has good anti-infl ammatory effect,can improve vascular endothelial function,can resist oxidation and thrombosis.Rosuvastatin has high clinical value in anti atherosclerosis,which is worth popularizing.
作者
安学军
AN Xue-jun(Lijin Second People's Hospital,Dongying 257447,China)
出处
《中国医药指南》
2020年第10期23-25,共3页
Guide of China Medicine
